Syneron
Latest round
- Series A
Last raised
- Nov 2024
Total raised
- Undisclosed
Investors
- 3
About Syneron
Established in 2022 and based in Guangzhou, China, Syneron operates as an AI pharmaceutical company that focuses on the development of artificial intelligence synthetic peptide new drugs. Xiao Zhang, the company's founder and CEO, is also the managing director of China Renaissance Capital. He graduated from Rutgers University in the United States and worked at CITIC Construction Investment Capital. The company's main business is the research and development of new synthetic peptide drugs using artificial intelligence. It has AI+synthetic peptide drug research and development platform SynCore. SynCore applies AI to the design, screening, synthesis, characterization, and optimization of synthetic peptide drugs. The platform can be used in the fields of innovative peptide drug research and development, enzyme engineering, etc. The company generates revenue by providing new synthetic peptide drugs.
Who invested in Syneron
3 investors across 1 round
See all investors in Syneron
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 19, 2024
Amount
Undisclosed
Investors
Questions about Syneron
Who invested in Syneron?
Syneron has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Syneron raised?
Syneron has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Syneron last raise money?
Syneron's most recent round on record is a Series A, in Nov 2024.
What does Syneron do?
Established in 2022 and based in Guangzhou, China, Syneron operates as an AI pharmaceutical company that focuses on the development of artificial intelligence synthetic peptide new drugs.
Where is Syneron headquartered?
Syneron is headquartered in Guangzhou, China.
Which VCs invest in companies like Syneron?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Syneron's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Syneron? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.